Dipna Pharmachem Limited has successfully obtained trading approval from BSE Limited for 22,44,000 fully paid-up equity shares issued through warrant conversion on a preferential basis. The approval, which became effective from January 20, 2026, marks the completion of a comprehensive application process initiated by the pharmaceutical company earlier in 2025.

Share Allotment Details

The equity shares carry specific parameters that define their structure and pricing:

The total value of the preferential allotment amounts to approximately ₹29.27 crores, calculated based on the issue price of ₹13.05 per share. These shares were issued pursuant to the conversion of warrants that were originally approved for issuance on a preferential basis.

Application Timeline and Process

The company followed a structured approach to obtain the necessary approvals:

• March 13, 2025: Submission of in-principle application to BSE for convertible warrants issuance
• December 9, 2025: Filing of listing application for equity shares pursuant to warrant conversion
• January 19, 2026: BSE issued approval letter and notice to trading members
• January 20, 2026: Trading approval became effective

The systematic progression through regulatory requirements demonstrates the company's compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, under Regulation 30.

Regulatory Compliance and Documentation

Dipna Pharmachem Limited, incorporated under CIN L24100GJ2011PLC066400, maintained transparency throughout the process by providing timely intimations to the stock exchange. The company's registered office is located at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad – 380055.

The approval was communicated through BSE's Notice No. 20260119-16 dated January 19, 2026, which was made available to all trading members of the exchange. This notice serves as the official communication regarding the listing and trading commencement of the newly issued equity shares.

Corporate Authorization

The regulatory filings were authorized by Keyur Dipakkumar Shah, Managing Director (DIN: 03167258), who digitally signed the intimation letter to BSE on January 21, 2026. The digital signature authentication confirms the authenticity and legal validity of the corporate communication submitted to the stock exchange.

This successful completion of the warrant conversion and subsequent trading approval enhances the company's equity base while providing liquidity options for the allottees in the secondary market.

Dipna Pharmachem Limited has issued a clarification to BSE Limited regarding significant movement in its stock price, stating that no material information exists within the company that could have caused such fluctuations. The response, dated January 21, 2026, addresses BSE's inquiry letter received on January 13, 2026.

Company's Official Response

In its formal communication to the stock exchange, Dipna Pharmachem clarified that it possesses no price-sensitive or material information that could result in significant movement of the company's scrip. The company emphasized its commitment to regulatory compliance under applicable SEBI regulations.

Regulatory Compliance Statement

The pharmaceutical company assured that it has made all necessary disclosures under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, within the stipulated time periods. These disclosures cover all information that may have a possible impact or cause fluctuation in the company's stock price.

Managing Director Keyur Dipakkumar Shah, holding DIN 03167258, digitally signed the response, confirming the company's position on the matter. The communication was sent from the company's registered office in Ahmedabad, Gujarat.

Market Volatility Attribution

Dipna Pharmachem specifically noted that currently there are no events, information, or announcements pending that require reporting to the stock exchange. The company attributed the observed price volatility to natural market forces rather than any company-specific developments.

The response concludes that the volatility in the company's stock price on the exchange is purely market-driven, suggesting that external market conditions rather than internal corporate developments are responsible for the price movements that prompted BSE's inquiry.